DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company will participate in upcoming investor conferences in May 2025.

2025 RBC Capital Markets Global Healthcare Conference
Tuesday, May 20^th – Wednesday, May 21^st, 2025, in New York City, New York. Management will be available for one-on-one meetings throughout the conference.

H.C. Wainwright 3^rd Annual BioConnect Conference
Tuesday, May 20^th, 2025, in New York City, New York. Management will participate in a fireside chat at 3:30 PM ET, which will be available via webcast at https://journey.ct.events/view/cb8be4c8-bb67-420a-b0a3-cf76483d9ff3. A replay will also be posted in the Investor Relations section of the Company’s website at www.diamedica.com.

22nd Annual Craig-Hallum Institutional Investor Conference
Wednesday, May 28, 2025 - Minneapolis, Minnesota. Management will be available for one-on-one meetings throughout the day.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia and acute ischemic stroke. DiaMedica’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.